Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01368588 · ClinicalTrials.gov registry record · Phase 3
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.
- Active
- Registry status
- Phase 3
- Development phase
- 2,592
- Enrollment target
- 20
- Study locations
NCT01368588: Active Phase 3 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.
NCT01368588 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by Radiation Therapy Oncology Group. The registered enrollment target is 2,592 participants, above the 605-participant average among 735 other Prostate Cancer trials with a reported enrollment target (328% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01368588, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by Radiation Therapy Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,592 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.
Primary Outcome
Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis.
Conditions Studied
Interventions
- RADIATION radiation therapy
- RADIATION Whole-pelvic radiotherapy (WPRT)
Study Locations (20)
Arizona
- Arizona Breast Cancer Specialists-Gilbert - Gilbert
- Arizona Center for Cancer Care-Peoria - Peoria
- Cancer Center at Saint Joseph's - Phoenix
- Saint Joseph's Hospital and Medical Center - Phoenix
- Arizona Breast Cancer Specialists-Phoenix - Phoenix
- Arizona Oncology-Deer Valley Center - Phoenix
- 21st Century Oncology-Scottsdale - Scottsdale
- Arizona Breast Cancer Specialists - Scottsdale
- Arizona Breast Cancer Specialists-Scottsdale - Scottsdale
- Arizona Oncology Services Foundation - Scottsdale
- Arizona Center for Cancer Care-Surprise - Surprise
- Arizona Oncology Associates-West Orange Grove - Tucson
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Alabama
- University of South Alabama Mitchell Cancer Institute - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,592 participants |
| Start Date | 2011-07 |
| Est. Completion | 2031-07 |
| Phase | Phase 3 |
What the registry record for NCT01368588 still lists
NCT01368588 is an interventional study that assigns participants to a tested intervention. Its 2,592 participants enrollment target places it among the larger protocols in the corpus, above the 605-participant average among 735 other Prostate Cancer trials with a reported enrollment target (328% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which radiation therapy is the first listed.
NCT01368588 names 20 study sites across 3 states, led by Arizona, Alaska, Alabama.
Frequently Asked Questions
What is clinical trial NCT01368588 about?
NCT01368588 is a clinical study titled "Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiat...
What is the current status of trial NCT01368588?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,592 participants. The study started on 2011-07. Estimated completion is 2031-07.
What conditions does trial NCT01368588 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01368588?
The interventions under investigation include: radiation therapy (RADIATION), Whole-pelvic radiotherapy (WPRT) (RADIATION).
Who is sponsoring clinical trial NCT01368588?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01368588 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01368588's enrollment target sits among peer trials
2,592 21st of 735 higher than 715 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia